Beliy Pyotr Aleksandrovich

Beliy Pyotr Aleksandrovich

Education

In 1987 he graduated from Moscow High School No. 47 (1264) with in-depth study of the English language.

In 2006, he graduated with honors from the Moscow State Medical and Dental University of the Federal Agency for Health and Social Development, was awarded the qualification "Doctor with a degree in Medical Medicine."

In 2008, he graduated with honors from the residency of the Moscow State Medical and Dental University of the Federal Agency for Health and Social Development, "was trained in clinical residency and completed a full course in Therapy.

Career

2015-2016

In 2015, Promomed acquired the Biochemist plant in Saransk, which became the company's main production site. The purchase of production facilities allowed the pharmaceutical company to expand its activities and increase the volume of production of drugs.

A year after the purchase of the plant, the company created a biotechnology laboratory to develop new drugs. The laboratory is engaged in the research and development of innovative medical products for various therapeutic directions.

2025: Net Worth - $1 billion

Pyotr Beliy, chairman of the board of directors of the pharmaceutical company Promomed, first entered the list of dollar billionaires with a fortune of more than $1 billion. The basis of its capital is 88% of the shares of PJSC Promomed, Forbes reported in June 2025. Now Beliy ranks fifth among Russian billionaires in the pharmaceutical industry, and his company is among the top 5 largest domestic pharmaceutical manufacturers.

Pharmaceutical company's operations are traded on the Moscow Exchange. On June 9, 2025, the cost of one Promomed security reached ₽420,85, which meant the cost of the Beliy package in the amount of ₽78,4 billion.

Promomed's portfolio includes more than 350 drugs for various purposes. Drugs in endocrinology and oncology account for about 60% of the pharmaceutical company's revenue.

Forbes notes that Beliy is the fifth Russian billionaire to earn capital in pharmaceuticals. Earlier, billionaires were co-owners of the Ogment Investments holding Viktor Kharitonin and Yegor Kulkov (they own shares in pharmaceutical manufacturers Pharmstandard, Otisipharm, Biocad and Generium), as well as founders of R-Pharm Alexey Repik and Farmasintez Vikram Punia. Also billionaires are the owners of pharmaceutical distributors: Protek group - Vadim Yakunin and FC Pulse companies - Eduard Netylko.^[1]